Disc Med­i­cine goes pub­lic in re­verse merg­er with strug­gling Gem­i­ni Ther­a­peu­tics

Af­ter li­cens­ing a failed Roche schiz­o­phre­nia drug last year, Disc Med­i­cine is go­ing pub­lic via a re­verse merg­er with Gem­i­ni Ther­a­peu­tics.

The com­bined com­pa­ny, while still named Disc Med­i­cine, will trade un­der the stock sym­bol $IRON, in ref­er­ence to Disc’s line­up of ther­a­pies for blood iron dis­or­ders. Along­side the merg­er, Disc has se­cured $53.5 mil­lion in an­oth­er fi­nanc­ing round, build­ing on the $90 mil­lion Se­ries B it raised in Sep­tem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER